Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Here’s a lovely paper from the Harrison lab @WEHI_research looking at how chromatin organisation changes during human T cell activation https://www.nature.com/articles/s41598-020-80165-9

New pre-print led by @S_Foroutan in our lab defines specific human CD8, CD4 T and NK cell exhaustion and residency signatures in colorectal cancer (CRC) and how their relative abundance impacts CRC patient outcomes. Huge effort by the team. Great EOY

https://www.biorxiv.org/content/10.1101/2020.12.19.423379v1

Well deserved recognition for @ProfSharonLewin picking up the top gong from @Committee4Melb A virologist and director, we collectively looked to Sharon for advice on Melbourne's response to the pandemic. An incredible response from a remarkable leader https://twitter.com/WISparkville/status/1330770627829977088

WISPP@WISparkville

Congratulations ⁦@ProfSharonLewin⁩ ! https://www.theage.com.au/politics/victoria/doherty-chief-awarded-top-gong-says-pandemic-has-changed-the-way-victorians-work-20201123-p56gzl.html

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are